Dosing & Uses
Dosage Forms & Strengths
capsule
- 50mg
- 100mg
Edema
100-300 mg/day PO qDay or divided q12hr
Hypertension (Off-label)
50-100 mg PO qDay or divided q12hr
Renal Impairment
CrCl <10 mL: Do not use
Hepatic Impairment
Reduce dose in patients with cirrhosis
Other Information
Monitor serum potassium
See also combo with HCTZ
Dosage Forms & Strengths
capsule
- 50mg
- 100mg
Hypertension (Off-label)
Safety & efficacy not established
1-2 mg/kg/day PO divided q12hr
Maximum dose: 3-4 mg/kg/day PO divided q12hr up to 300 mg/day
Consider lower initial doses
Edema
50-300 mg/day PO qDay or divided q12hr
Hypertension
50-300 mg/day PO qDay or divided q12hr
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (10)
- amiloride
amiloride and triamterene both increase serum potassium. Avoid or Use Alternate Drug.
amiloride, triamterene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia. - cyclosporine
triamterene and cyclosporine both increase serum potassium. Avoid or Use Alternate Drug. Coadministration not recommended
- drospirenone
drospirenone and triamterene both increase serum potassium. Avoid or Use Alternate Drug.
drospirenone, triamterene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia. - eplerenone
triamterene, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.
- lofexidine
lofexidine, triamterene. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.
- potassium acid phosphate
triamterene and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.
- potassium chloride
triamterene and potassium chloride both increase serum potassium. Avoid or Use Alternate Drug.
- potassium citrate
triamterene and potassium citrate both increase serum potassium. Avoid or Use Alternate Drug.
- potassium phosphates, IV
triamterene and potassium phosphates, IV both increase serum potassium. Avoid or Use Alternate Drug.
- spironolactone
spironolactone and triamterene both increase serum potassium. Avoid or Use Alternate Drug.
spironolactone, triamterene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.
Monitor Closely (141)
- acebutolol
acebutolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- aceclofenac
triamterene and aceclofenac both increase serum potassium. Modify Therapy/Monitor Closely.
- acemetacin
triamterene and acemetacin both increase serum potassium. Modify Therapy/Monitor Closely.
- albuterol
triamterene increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- aldesleukin
aldesleukin increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- amantadine
triamterene increases levels of amantadine by decreasing elimination. Use Caution/Monitor.
- amifostine
amifostine, triamterene. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.
- amiodarone
amiodarone will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- arformoterol
triamterene increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- aspirin
triamterene and aspirin both increase serum potassium. Modify Therapy/Monitor Closely.
- aspirin rectal
triamterene and aspirin rectal both increase serum potassium. Modify Therapy/Monitor Closely.
- aspirin/citric acid/sodium bicarbonate
triamterene and aspirin/citric acid/sodium bicarbonate both increase serum potassium. Modify Therapy/Monitor Closely.
- atenolol
atenolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- avanafil
avanafil increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- benazepril
benazepril and triamterene both increase serum potassium. Use Caution/Monitor.
- bendroflumethiazide
triamterene increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- betaxolol
betaxolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- bisoprolol
bisoprolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- bretylium
triamterene, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.
- bumetanide
triamterene increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection decreases effects of triamterene by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Opioids can reduce diuretic efficacy by inducing antidiuretic hormone release.
- canagliflozin
triamterene and canagliflozin both increase serum potassium. Use Caution/Monitor.
- candesartan
candesartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- captopril
captopril, triamterene. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Increased risk of hyperkalemia. Monitor blood pressure and potassium.
- carbenoxolone
triamterene increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- carbidopa
carbidopa increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.
- carvedilol
carvedilol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- celecoxib
triamterene and celecoxib both increase serum potassium. Modify Therapy/Monitor Closely.
- celiprolol
celiprolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- chlorothiazide
triamterene increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- chlorthalidone
triamterene increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- choline magnesium trisalicylate
triamterene and choline magnesium trisalicylate both increase serum potassium. Modify Therapy/Monitor Closely.
- cimetidine
cimetidine will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- cyclopenthiazide
triamterene increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- dalteparin
triamterene, dalteparin. Either increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels.
- dichlorphenamide
dichlorphenamide, triamterene. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- diclofenac
triamterene and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.
- diflunisal
triamterene and diflunisal both increase serum potassium. Modify Therapy/Monitor Closely.
- digoxin
digoxin will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
triamterene and digoxin both increase serum potassium. Modify Therapy/Monitor Closely. - disopyramide
triamterene increases effects of disopyramide by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiovascular depression.
- dobutamine
triamterene increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- dofetilide
dofetilide will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- dopexamine
triamterene increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- empagliflozin
empagliflozin, triamterene. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of empagliflozin with diuretics results in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.
- enalapril
enalapril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- enoxaparin
triamterene, enoxaparin. Either increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels.
- ephedrine
triamterene increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- epinephrine
triamterene increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- epinephrine racemic
triamterene increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- eprosartan
eprosartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- esmolol
esmolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- ethacrynic acid
triamterene increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- etodolac
triamterene and etodolac both increase serum potassium. Modify Therapy/Monitor Closely.
- fenbufen
triamterene and fenbufen both increase serum potassium. Modify Therapy/Monitor Closely.
- fenoprofen
triamterene and fenoprofen both increase serum potassium. Modify Therapy/Monitor Closely.
- fentanyl
fentanyl decreases effects of triamterene by Other (see comment). Modify Therapy/Monitor Closely. Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).
- fentanyl intranasal
fentanyl intranasal decreases effects of triamterene by Other (see comment). Modify Therapy/Monitor Closely. Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).
- fentanyl transdermal
fentanyl transdermal decreases effects of triamterene by Other (see comment). Modify Therapy/Monitor Closely. Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).
- fentanyl transmucosal
fentanyl transmucosal decreases effects of triamterene by Other (see comment). Modify Therapy/Monitor Closely. Comment: Fentanyl can reduce the efficacy of diuretics by inducing antidiuretic hormone release. Fentanyl may also lead to acute urinary retention by causing bladder sphincter spasm (particularly in men with enlarged prostates).
- finerenone
triamterene and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.
- flurbiprofen
triamterene and flurbiprofen both increase serum potassium. Modify Therapy/Monitor Closely.
- formoterol
triamterene increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- fosinopril
fosinopril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- furosemide
triamterene increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- gentamicin
triamterene increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- heparin
triamterene, heparin. Either increases toxicity of the other by serum potassium. Use Caution/Monitor. Both drugs may increase serum potassium levels.
- hydrochlorothiazide
triamterene increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- ibuprofen
triamterene and ibuprofen both increase serum potassium. Modify Therapy/Monitor Closely.
- ibuprofen IV
triamterene, ibuprofen IV. Other (see comment). Modify Therapy/Monitor Closely. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
triamterene and ibuprofen IV both increase serum potassium. Modify Therapy/Monitor Closely. - imidapril
imidapril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- indapamide
triamterene increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- indomethacin
triamterene and indomethacin both increase serum potassium. Modify Therapy/Monitor Closely.
- irbesartan
irbesartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- isoproterenol
triamterene increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- juniper
juniper, triamterene. Other (see comment). Use Caution/Monitor. Comment: Juniper may potentiate or interfere with diuretic therapy. Juniper has diuretic effects, but may cause kidney damage at large doses.
- ketoprofen
triamterene and ketoprofen both increase serum potassium. Modify Therapy/Monitor Closely.
- ketorolac
triamterene and ketorolac both increase serum potassium. Modify Therapy/Monitor Closely.
- ketorolac intranasal
triamterene and ketorolac intranasal both increase serum potassium. Modify Therapy/Monitor Closely.
- labetalol
labetalol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- levalbuterol
triamterene increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- levodopa
levodopa increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.
- lisinopril
lisinopril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- lornoxicam
triamterene and lornoxicam both increase serum potassium. Modify Therapy/Monitor Closely.
- losartan
losartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- maraviroc
maraviroc, triamterene. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.
- meclofenamate
triamterene and meclofenamate both increase serum potassium. Modify Therapy/Monitor Closely.
- mefenamic acid
triamterene and mefenamic acid both increase serum potassium. Modify Therapy/Monitor Closely.
- meloxicam
triamterene and meloxicam both increase serum potassium. Modify Therapy/Monitor Closely.
- metaproterenol
triamterene increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- methyclothiazide
triamterene increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely. .
- methylphenidate transdermal
methylphenidate transdermal decreases effects of triamterene by anti-hypertensive channel blocking. Use Caution/Monitor.
- metolazone
triamterene increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- metoprolol
metoprolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- moexipril
moexipril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- nabumetone
triamterene and nabumetone both increase serum potassium. Modify Therapy/Monitor Closely.
- nadolol
nadolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- naproxen
triamterene and naproxen both increase serum potassium. Modify Therapy/Monitor Closely.
- nebivolol
nebivolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- nitroglycerin rectal
nitroglycerin rectal, triamterene. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .
- noni juice
triamterene and noni juice both increase serum potassium. Use Caution/Monitor.
- norepinephrine
triamterene increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- oliceridine
oliceridine decreases effects of triamterene by Other (see comment). Use Caution/Monitor. Comment: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor for signs of diminished diuresis and/or effects on blood pressure and increase dosage of the diuretic as needed. .
- olmesartan
olmesartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- oxaprozin
triamterene and oxaprozin both increase serum potassium. Modify Therapy/Monitor Closely.
- parecoxib
triamterene and parecoxib both increase serum potassium. Modify Therapy/Monitor Closely.
- penbutolol
penbutolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- perindopril
perindopril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- pindolol
pindolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- pirbuterol
triamterene increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- piroxicam
triamterene and piroxicam both increase serum potassium. Modify Therapy/Monitor Closely.
- pivmecillinam
pivmecillinam increases effects of triamterene by unspecified interaction mechanism. Use Caution/Monitor. Hyperkalemia.
- potassium citrate/citric acid
triamterene and potassium citrate/citric acid both increase serum potassium. Use Caution/Monitor.
- procainamide
procainamide will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- propranolol
propranolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- quinapril
quinapril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- quinidine
quinidine will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.
- ramipril
ramipril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- sacubitril/valsartan
sacubitril/valsartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- salicylates (non-asa)
triamterene and salicylates (non-asa) both increase serum potassium. Modify Therapy/Monitor Closely.
- salmeterol
triamterene increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- salsalate
triamterene and salsalate both increase serum potassium. Modify Therapy/Monitor Closely.
- sotalol
sotalol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- sparsentan
sparsentan and triamterene both increase serum potassium. Use Caution/Monitor. Monitor serum potassium frequently.
- succinylcholine
triamterene and succinylcholine both increase serum potassium. Modify Therapy/Monitor Closely.
- sulfasalazine
triamterene and sulfasalazine both increase serum potassium. Modify Therapy/Monitor Closely.
- sulindac
triamterene and sulindac both increase serum potassium. Modify Therapy/Monitor Closely.
- tadalafil
tadalafil increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- telmisartan
telmisartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- temocillin
temocillin increases effects of triamterene by unspecified interaction mechanism. Use Caution/Monitor. Hyperkalemia.
- terbutaline
triamterene increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- ticarcillin
ticarcillin increases effects of triamterene by unspecified interaction mechanism. Use Caution/Monitor. Hyperkalemia.
- timolol
timolol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- tolfenamic acid
triamterene and tolfenamic acid both increase serum potassium. Modify Therapy/Monitor Closely.
- tolmetin
triamterene and tolmetin both increase serum potassium. Modify Therapy/Monitor Closely.
- tolvaptan
triamterene and tolvaptan both increase serum potassium. Modify Therapy/Monitor Closely.
- torsemide
triamterene increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.
- trandolapril
trandolapril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.
- trimethoprim
trimethoprim and triamterene both increase serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.
- valsartan
valsartan and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
- voclosporin
voclosporin and triamterene both increase serum potassium. Use Caution/Monitor.
- xipamide
xipamide increases effects of triamterene by pharmacodynamic synergism. Use Caution/Monitor.
Minor (77)
- aceclofenac
triamterene, aceclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
aceclofenac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - acemetacin
triamterene, acemetacin. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
acemetacin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - agrimony
agrimony increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- aspirin
triamterene, aspirin. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
aspirin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - aspirin rectal
triamterene, aspirin rectal. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
aspirin rectal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.
triamterene, aspirin/citric acid/sodium bicarbonate. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity. - birch
birch increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- brimonidine
brimonidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- cadexomer iodine
cadexomer iodine, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- calcium acetate
triamterene decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.
- calcium carbonate
triamterene decreases levels of calcium carbonate by increasing renal clearance. Minor/Significance Unknown.
- calcium chloride
triamterene decreases levels of calcium chloride by increasing renal clearance. Minor/Significance Unknown.
- calcium citrate
triamterene decreases levels of calcium citrate by increasing renal clearance. Minor/Significance Unknown.
- calcium gluconate
triamterene decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown.
- celecoxib
triamterene, celecoxib. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
celecoxib increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - choline magnesium trisalicylate
triamterene, choline magnesium trisalicylate. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
choline magnesium trisalicylate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - cornsilk
cornsilk increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- diclofenac
triamterene, diclofenac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
diclofenac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - diflunisal
triamterene, diflunisal. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
diflunisal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - entecavir
triamterene, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
- epoprostenol
epoprostenol increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- etodolac
triamterene, etodolac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
etodolac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - fenbufen
triamterene, fenbufen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
- fenoprofen
triamterene, fenoprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
fenoprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - flurbiprofen
triamterene, flurbiprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
flurbiprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - folic acid
triamterene decreases levels of folic acid by increasing renal clearance. Minor/Significance Unknown.
- forskolin
forskolin increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- goldenrod
goldenrod increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- hydrochlorothiazide
hydrochlorothiazide will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- ibuprofen
triamterene, ibuprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
ibuprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - ibuprofen IV
ibuprofen IV increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.
- indomethacin
triamterene, indomethacin. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
indomethacin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - iodinated glycerol
iodinated glycerol, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- iodine
iodine, triamterene. Mechanism: decreasing renal clearance. Minor/Significance Unknown. Hyperkalemia.
- ketoprofen
triamterene, ketoprofen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
ketoprofen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - ketorolac
triamterene, ketorolac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
ketorolac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - ketorolac intranasal
triamterene, ketorolac intranasal. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
ketorolac intranasal increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - L-methylfolate
triamterene decreases levels of L-methylfolate by increasing renal clearance. Minor/Significance Unknown.
- lornoxicam
triamterene, lornoxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
lornoxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - magnesium chloride
triamterene increases levels of magnesium chloride by decreasing renal clearance. Minor/Significance Unknown.
- magnesium citrate
triamterene increases levels of magnesium citrate by decreasing renal clearance. Minor/Significance Unknown.
- magnesium hydroxide
triamterene increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown.
- magnesium oxide
triamterene increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown.
- magnesium sulfate
triamterene increases levels of magnesium sulfate by decreasing renal clearance. Minor/Significance Unknown.
- maitake
maitake increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- meclofenamate
meclofenamate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity.
triamterene, meclofenamate. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity. - mefenamic acid
triamterene, mefenamic acid. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
mefenamic acid increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - meloxicam
triamterene, meloxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
meloxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - memantine
memantine will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- metformin
metformin will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- methyclothiazide
methyclothiazide will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- midodrine
midodrine will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- minoxidil
triamterene increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.
- nabumetone
triamterene, nabumetone. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
nabumetone increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - naproxen
triamterene, naproxen. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
naproxen increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - octacosanol
octacosanol increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- ofloxacin
ofloxacin will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- oxaprozin
triamterene, oxaprozin. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
oxaprozin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - parecoxib
triamterene, parecoxib. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
parecoxib increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - piroxicam
triamterene, piroxicam. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
piroxicam increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - pramipexole
pramipexole will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- quinine
quinine will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
- reishi
reishi increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- salicylates (non-asa)
triamterene, salicylates (non-asa). Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
salicylates (non-asa) increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - salsalate
triamterene, salsalate. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
salsalate increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - shepherd's purse
shepherd's purse, triamterene. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.
- sulfadiazine
triamterene increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown.
- sulfamethoxazole
sulfamethoxazole will increase the level or effect of triamterene by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
triamterene, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.
triamterene increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown. - sulfasalazine
triamterene, sulfasalazine. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
sulfasalazine increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - sulfisoxazole
triamterene increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown.
- sulindac
triamterene, sulindac. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
sulindac increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - tizanidine
tizanidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.
- tolfenamic acid
triamterene, tolfenamic acid. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
tolfenamic acid increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - tolmetin
triamterene, tolmetin. Other (see comment). Minor/Significance Unknown. Comment: Risk of acute renal failure. Mechanism: NSAIDs decrease prostaglandin synthesis, which normally protect against nephrotoxicity.
tolmetin increases toxicity of triamterene by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. - treprostinil
treprostinil increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.
- trimethoprim
triamterene will increase the level or effect of trimethoprim by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
triamterene, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia. - verapamil
triamterene will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.
Adverse Effects
1-10%
CHF
Edema
Hypotension
Dizziness
Fatigue
HA
Photosensitivity
Rash
Diarrhea
Nausea
Vomiting
Hyperuricemia
Nephrotoxicity
Frequency Not Defined
GI upset
Thrombocytopenia
Nephrolithiasis
Folic acid antagonism
Warnings
Contraindications
Hypersensitivity to triamterene
Anuria, severe liver disease, renal failure
Hyperkalemia
Concomitant use with K+-sparing diuretic, or K supplementation
Cautions
Use caution in acid-base imbalance, electrolyte abnormalities, hyperuricemia or gout, liver disease, renal impairment, renal stones
Patients should be observed regularly for possible occurrence of blood dyscrasias, liver damage or other idiosyncratic reactions
Periodic BUN and serum potassium determinations should be made to check kidney function, especially in patients with suspected or confirmed renal insufficiency; particularly important to make serum potassium determinations in elderly or diabetic patients receiving drug; these patients should be observed carefully for possible serum potassium increases
Electrolyte imbalance often encountered in diseases such as congestive heart failure, renal disease or cirrhosis may be aggravated or caused independently by any effective diuretic agent including triamterene; use of full doses of a diuretic when salt intake is restricted can result in a low-salt syndrome
Triamterene can cause mild nitrogen retention, which is reversible upon withdrawal of drug and is seldom observed with intermittent (every-other-day) therapy
Therapy may cause a decreasing alkali reserve, with possibility of metabolic acidosis
By the very nature of their illness, cirrhotics with splenomegaly sometimes have marked variations in their blood; since triamterene is a weak folic acid antagonist, it may contribute to appearance of megaloblastosis in cases where folic acid stores have been depleted; periodic blood studies in these patients recommended; observe also for exacerbations of underlying liver disease
Triamterene has elevated uric acid, especially in persons predisposed to gouty arthritis
Triamterene reported in renal stones in association with other calculus components; drug should be used with caution in patients with histories of renal stones
Interferes with fluorescent assay of quinidine
Not recommended for pregnancy-induced HTN; use during pregnancy may increase risk of cardiovascular defects and oral cleft in child
Hyperkalemia
- Drug tends to conserve potassium rather than to promote excretion as do many diuretics and, occasionally, can cause increases in serum potassium which, in some instances, can result in hyperkalemia; in rare instances, hyperkalemia has been associated with cardiac irregularities
- If hyperkalemia present or suspected, obtain an electrocardiogram; if tECG shows no widening of QRS or arrhythmia in presence of hyperkalemia, it is usually sufficient to discontinue therapy and any potassium supplementation, and substitute a thiazide alone
- Sodium polystyrene sulfonate may be administered to enhance excretion of excess potassium; presence of a widened QRS complex or arrhythmia in association with hyperkalemia requires prompt additional therapy
- For tachyarrhythmia, infuse 44 mEq of sodium bicarbonate or 10 mL of 10% calcium gluconate or calcium chloride over several minutes; for asystole, bradycardia or A-V block transvenous pacing is also recommended
- Effect of calcium and sodium bicarbonate is transient and repeated administration may be required; when indicated by clinical situation, excess K+ may be removed by dialysis or oral or rectal administration of Kayexalate®. Infusion of glucose and insulin has also been used to treat hyperkalemia
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Discontinue drug or nursing
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Direct effect on renal distal tubule to inhibit Na+ reabsorption
Inhibits Na/K-ATPase, decreases Ca++ , Mg++ and hydrogen excretion
Pharmacokinetics
Half-Life: 1.5-2.5 hr
Duration: 7-9 hr
Onset: Initial effect: 2-4 hr; Max effect: diuresis: several days, HTN: 2-3 months
Peak Plasma Time: 1.5-3 hr
Bioavailability: 30-70%
Protein Bound: 55-67%
Metabolism: Liver
Metabolites: hydroxytriamterene sulfate (active)
Excretion: urine 21%
Dialyzable: Yes (hemodialysis)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Dyrenium oral - | 100 mg capsule |  | |
| Dyrenium oral - | 50 mg capsule |  | |
| triamterene oral - | 50 mg capsule | | |
| triamterene oral - | 50 mg capsule |  | |
| triamterene oral - | 100 mg capsule |  | |
| triamterene oral - | 100 mg capsule | |
Copyright © 2010 First DataBank, Inc.
Patient Handout
triamterene oral
TRIAMTERENE - ORAL
(trye-AM-ter-een)
COMMON BRAND NAME(S): Dyrenium
WARNING: This medication can increase your potassium levels, especially if you have kidney disease or diabetes, or are severely ill. Potassium levels must be done while you are taking this medication. If not treated, very high potassium levels can sometimes be fatal. If you notice any of the following serious side effects, tell your doctor right away: muscle weakness, slow/irregular heartbeat.
USES: Triamterene is a "water pill" (diuretic) that works in your kidneys to increase the amount of urine you make. This helps your body get rid of extra water. This medication is used to decrease swelling (edema) caused by conditions such as cancer, heart failure, liver disease, and kidney disease. This effect can help your kidneys work better and lessen symptoms such as trouble breathing and swelling in your ankles, feet, hands, or belly.
HOW TO USE: Take this medication by mouth as directed by your doctor, usually once or twice a day after a meal. If you take this drug too close to bedtime, you may need to wake up to urinate. It is best to take this medication at least 4 hours before your bedtime.To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully.The dosage is based on your medical condition and response to treatment.Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Your dose may need to be gradually decreased.Tell your doctor if you do not get better or if you get worse.
SIDE EFFECTS: See also Warning section.Dizziness, lightheadedness, tiredness, headache, stomach upset, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Triamterene can cause dehydration and electrolyte imbalance. Tell your doctor right away if you have any symptoms of dehydration or electrolyte imbalance, such as confusion, unusual dry mouth/thirst, fast/irregular heartbeat, severe dizziness/lightheadedness, or seizures.Tell your doctor right away if you have any serious side effects, including: nausea/vomiting that doesn't stop, stomach/abdominal pain, yellowing eyes/skin, dark urine, signs of infection (such as sore throat that doesn't go away, fever, chills, cough), signs of kidney problems (such as pain in the side/back/abdomen, painful urination, blood in the urine, change in the amount of urine), joint pain (such as big toe pain), easy bruising/bleeding.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also Warning section.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems (such as kidney stones), liver disease, mineral imbalance (such as high potassium blood level, low sodium blood level), dehydration, gout, conditions causing low folic acid blood levels (such as alcoholic cirrhosis, pregnancy).This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).If you have diabetes, triamterene may affect your blood sugar. Check your blood sugar regularly as directed and share the results with your doctor. Tell your doctor right away if you have symptoms of high blood sugar such as increased thirst/urination. Your doctor may need to adjust your diabetes medication, exercise program, or diet.Severe sweating, diarrhea, or vomiting may cause dehydration and cause you to feel lightheaded. Tell your doctor if you have severe diarrhea or vomiting. To prevent dehydration, drink plenty of fluids unless your doctor tells you not to.This medication may increase your potassium levels. Before using potassium supplements or salt substitutes that contain potassium, consult your doctor or pharmacist.This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially high potassium blood levels.During pregnancy, this medication should be used only when clearly needed. It may harm an unborn baby. Discuss the risks and benefits with your doctor.This drug may pass into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also Precautions section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: drugs that may increase the level of potassium in the blood (such as amiloride, cyclosporine, eplerenone, tacrolimus, birth control pills containing drospirenone), lithium.Some products have ingredients that could raise your blood pressure or worsen your swelling. Tell your pharmacist what products you are using, and ask how to use them safely (especially cough-and-cold products, diet aids, or NSAIDs such as ibuprofen/naproxen).This medication may interfere with certain lab tests, possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness, muscle weakness, slow/irregular heartbeat.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as potassium levels, kidney/liver function) should be done while you are taking this medication. Keep all medical and lab appointments.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised November 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
